CART123 + Ruxolitinib in Relapsed/Refractory AML

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
CART123 + Ruxolitinib in Relapsed/Refractory AML	Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Active, not recruiting	Phase 1	2026-01-16		NCT06768476

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis	114
University of Pennsylvania	502

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of Pennsylvania	Philadelphia	United States	507

Clinical trials